Sugi Predict

Sugi Predict / Compounds / SCHEMBL1147211

SCHEMBL1147211

SCHEMBL1147211

O=C(O)C1(O)CCN(Cc2ccccc2)CC1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ OPRL1 P41146 2/20 0.63
▸ POLB P06746 1/20 0.61
▸ CYP2D6 P10635 6/20 0.59
▸ CHRM2 P08172 3/20 0.57
▸ CHRM3 P20309 1/20 0.57
▸ CYP3A4 P08684 4/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ SIGMAR1 Q99720 1/20 0.57
▸ CCR3 P51677 1/20 0.56
▸ TSHR P16473 3/20 0.55
▸ ALDH1A1 P00352 5/20 0.54
▸ USP2 O75604 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ CYP2C19 P33261 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ HIF1A Q16665 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL25235306 0.98 POLB (0.64) OPRL1POLBCYP2D6CHRM2CHRM3
SCHEMBL11544321 0.92 OPRL1 (0.57) OPRL1POLBCYP2D6CHRM2CHRM3
SCHEMBL63806 0.87 TSHR (0.63) OPRL1POLBCYP2D6CHRM2CHRM3
SCHEMBL11888852 0.85 ALDH1A1 (0.56) OPRL1ALDH1A1MEN1KMT2A
SCHEMBL14456684 0.85 CYP3A4 (0.59) OPRL1CYP2D6CYP3A4TSHRALDH1A1
SCHEMBL3498095 0.83 CYP2D6 (0.56) OPRL1POLBCYP2D6CHRM2CHRM3
SCHEMBL11888851 0.83 SIGMAR1 (0.58) OPRL1POLBCYP2D6CYP3A4SIGMAR1
SCHEMBL11355073 0.82 GAA (0.54) OPRL1POLBCYP2D6CHRM2CHRM3
SCHEMBL11353776 0.82 CYP2D6 (0.59) OPRL1CYP2D6CYP3A4HSD17B10TSHR
SCHEMBL28548988 0.82 OPRL1 (0.71) OPRL1POLBCYP2D6CHRM2CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102471265-B Piperidine derivatives and their use for the treatment of obesity, diabetes, dyslipidemia and atherosclerosis HOFFMANN LA ROCHE 2014-09-03 — — CN claimed
EP-2480532-B1 PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS HOFFMANN LA ROCHE (CH) 2013-11-20 — — EP claimed
EP-2480532-A1 PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS F. Hoffmann-La Roche AG (CH) 2012-08-01 — — EP claimed
CN-102471265-A Piperidine derivatives and their use for the treatment of obesity, diabetes, dyslipidemia and atherosclerosis HOFFMANN LA ROCHE 2012-05-23 — — CN claimed
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 — — EP disclosed
WO-2024233846-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES, INC. (US) 2024-11-14 — — WO disclosed
US-20240124428-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2024-04-18 — — US disclosed
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2023-11-02 — — US disclosed
EP-4263520-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2023-10-25 — — EP disclosed
WO-2022133529-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2022-06-30 — — WO disclosed
CN-108368090-B Compounds as immunomodulators 百时美施贵宝公司 2022-04-12 — — CN disclosed
WO-2021043116-A1 BIPHENYL COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国药科大学 2021-03-11 — — WO disclosed
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2011-02-03 — — US disclosed
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2011-02-03 — — US disclosed
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2011-02-03 — — US disclosed
WO-2011012602-A1 PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS F. HOFFMANN-LA ROCHE AG (CH) 2011-02-03 — — WO disclosed
WO-2011012602-A1 PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS F. HOFFMANN-LA ROCHE AG (CH) 2011-02-03 — — WO disclosed
US-20100168154-A1 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-07-01 — — US disclosed
EP-2149560-A1 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND Astellas Pharma Inc. (JP) 2010-02-03 — — EP disclosed
US-4166114-A AMINOGLYCOSIDE ANTIBIOTIC DERIVATIVES AND METHOD OF USE SHIONOGI & CO., LTD. (JP) 1979-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF AR, NR5A1, SHBG OPRL1 957/4885POLB 2788/4885CYP2D6 1007/4885
US-20240124428-A1 HETEROCYCLIC INHIBITORS OF PCSK9 PCSK9, PCSK7, PCSK6 OPRL1 1730/4885POLB 2895/4885CYP2D6 1057/4885
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES ADRA1D, ADORA1, H1-0 OPRL1 403/4885POLB 2222/4885CYP2D6 218/4885
US-20100168154-A1 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND CACNA1S, CACNA1E, CACNA1B OPRL1 9/4885POLB 2934/4885CYP2D6 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.